Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Table 2 Estimation of initial distribution of visual acuity for the model from MARINA data [2].

MARINA		Model
Visual acuity*	Number (%) of patients ^†	Visual acuity (letters)	Proportion of patients
		90	0%
20/40 or better (≥ 70 letters)	99 (13.8%)	75	14%
Better than 20/200 but worse than 20/40 (>35 but < 70 letters)*	519 (72.5%)^‡	60	36%
		45	36%
20/200 or worse (≤ 35 letters)	98(13.7%)	30	14%

* The eligibility criteria for the trial required patients to have a best corrected visual acuity of between 20/40 (70 letters) and 20/320 (25 letters).
^† Data from the three treatment arms were pooled.
‡ Half the patients in this visual acuity group were assigned to the 60 letter state in the Model and half were assigned to the 45 letter state.

ISSN: 1478-7547